Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, discusses cost-saving implications of biosimilars in oncology, as well as several barriers that continue to impede their use.
Kathy Oubre, MS, is the chief operating officer of Pontchartrain Cancer Center.
Transcript
There are several challenges to biosimilar integration in cancer care, particularly intervention from payers in allowing access to providers. How has this issue fared in recent years and what other barriers persist?
Payers continue to insert their influence in the physician-patient relationship by step edits and formulary restrictions. For example, biosimilars are often not preferred over reference products by the majority of US health care plans.
In addition, biosimilars are also not even on the formulary of most of our state Medicaids, and physician preference has been slow to adoption. A 2019 survey found that the majority of oncology products still are not used with biosimilars or they're used only in supportive care or some physicians prefer not to switch patients during a launch.
On a bright note, though, the recent Bernstein analysis that I mentioned earlier shows that these attitudes are changing. And even with the most modest uptake and challenges around biosimilar adoption, a recent IQVIA report shows that biosimilar-related savings will range from $49 to $140 billion over the next 5 years.
How has the pandemic impacted biosimilar adoption in cancer care delivery?
I think that answer has 2 parts. Similar to most drug launches during COVID-19, it's just been really difficult to keep up with new biosimilar drug launches during this time due to lack of access with our pharma partners.
However, as many people continue to have their hours cut or lose their jobs and just be faced with financial insecurities during this time, the cost savings of biosimilars have helped many people be able to continue and afford their treatments.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
What We’re Reading: HHS' Funding Flat; Mifepristone Safety; Insulin Shortage
March 25th 2024Flat funding for Health and Human Services (HHS) leaves critical health initiatives stagnant; Supreme Court weighs tightening regulations on abortion pill; manufacturing delay sparks access concerns for insulin medication.
Read More